Led · Series A · Jun 2025

Mosanna Therapeutics is a clinical-stage biotech pioneering a pharmaceutical approach to obstructive sleep apnea with an easily administered nighttime nasal spray, MOS118. MOS118 targets upper airway muscles to restore the body's natural airway reflex and is currently being evaluated in a Phase 1 clinical trial. The company says decreased activity of the natural airway reflex during sleep results in loss of airway patency in OSA patients, and MOS118 aims to correct that dysfunction. The new financing will support advancement of MOS118 through Phase 2 development and will also fund expansion of Mosanna's pipeline. Mosanna appointed David Weber, Ph.D., as President and Chief Executive Officer to lead clinical development and serve on the board. Founded in 2022, the company has offices in Redwood City, California and Basel, Switzerland, and has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High‑Tech Gründerfonds (HTGF). Mosanna Therapeutics is developing MOS-118 (formerly AVE0118), a small-molecule nasal spray acquired from Sanofi, as a targeted treatment for Metabolic Obstructive Sleep Apnea (MOSA). MOSA is characterized by upper-airway obstruction during sleep that reduces blood oxygen, raises cardiac load, and increases cardiovascular mortality risk, and it also causes daytime sleepiness and cognitive problems. The company aims to deliver an effective, well-tolerated precision medicine to patients and notes hundreds of millions are affected globally. Mosanna plans a first Phase 1b clinical trial by end-2023. The recently completed seed financing will fund formulation and manufacturing optimization and regulatory activities to enable that trial. Leadership includes co-founder and CEO Jonathan Talbot and newly appointed Chairman Ben Machielse.

Led · Series A · Jan 2025

Relief Cardiovascular is a privately held medical device company and an inQB8 Medical Technologies portfolio company focused on improving outcomes for patients with heart failure. Its flagship product, the Relief System, is a transcatheter smart implant that uses a "puller" mechanism and integrated sensors to autonomously capture renal vein pressures and multiparametric data. The system is designed to both monitor renal pressures and therapeutically modulate them, providing physicians actionable data to optimize fluid management—including for diuretic-resistant heart failure. The company plans to use new funding to advance product development and to initiate a first-in-human feasibility study to evaluate the safety and efficacy of the Relief System. Relief Cardiovascular has closed a $12M Series A to support these activities and is advancing toward human clinical studies. The company was founded and incubated within inQB8 Medical Technologies and is based in Irvine, Calif.

Led · Seed · Dec 2024

Alveron Pharma is a clinical-stage company developing OKL-1111, a synthetic agent intended to reverse anticoagulants and platelet inhibitors and prevent haematoma expansion in intracranial haemorrhage (ICH). OKL-1111 binds to a downstream clotting factor and is designed for rapid IV administration, potentially within 10 minutes of a diagnostic CT scan. The drug also reportedly reverses the effects of clopidogrel, for which there is currently no antidote. Founded in 2019 and based in Nijmegen, Netherlands, Alveron positions OKL-1111 as a first-line therapy to reduce door-to-needle time and improve clinical outcomes including mortality and morbidity. Financially, the company completed a €5.0M Series Seed extension (approx $5.28M) to accelerate development. Proceeds will support activities to ready OKL-1111 for further clinical studies aimed at demonstrating safety and proof-of-concept efficacy in patients.

Led · Series B · Sep 2024

CorFlow Therapeutics is developing the CoFl system to provide timely, accurate detection of microvascular obstruction (MVO) in the cath lab immediately after stent implantation and to enable localized delivery of therapeutics to the microvasculature. The technology integrates with standard guide catheter and wire access and is intended to both diagnose MVO and deliver treatments at the point of care. CorFlow has reported recent data from over 70 patients in its first-in-human MOCA I trial and an extensive preclinical program supporting its approach. The company plans a MOCA II pivotal IDE trial in the US and Europe to validate CoFl against contrast-enhanced cardiac MRI and to support US market clearance. It will also run an adaptive platform therapy study in Europe to evaluate multiple therapeutic agents delivered via CoFl and measure clinical and imaging outcomes up to six months. Headquartered in Baar, Switzerland and founded in 2016, CorFlow is collaborating with academic partners including the University of Bern, ETH Zurich and University Hospital Zurich. CorFlow Therapeutics develops the Controlled Flow Infusion (CoFITM) system and a proprietary dynamic Microvascular Resistance (dMVRTM) concept to detect and treat microvascular obstruction (MVO) in the cathlab. The CoFITM system is positioned as a combined diagnostic and therapeutic technology that enables detection and low-flow infusion treatment of MVO immediately after reopening epicardial arteries. Seed proceeds will finance the First-in-Man MOCA I (MVO with CoFITM System Assessment) safety and feasibility trial in 40 acute heart attack patients. MOCA I will measure peri-procedural dMVR and compare those values to post-procedure contrast-enhanced MRI, and will investigate low-flow infusion of approved therapeutic agents to reduce MVO. The company cites that around 50% of acute heart attack patients develop MVO, translating to roughly 200,000 patients annually, and notes MVO is an independent predictor of heart failure and death. CorFlow has presented nonclinical data at major cardiology meetings (ACC, EuroPCR, ESC) and plans further presentation at TCT; it aims to raise a Series A in 2019 to secure longer-term R&D, clinical, and regulatory activities. CorFlow Therapeutics is developing proprietary technologies to diagnose and treat microvascular obstructions (MVO) in severe heart attack patients. Its technologies aim to enable interventional cardiologists to diagnose and treat MVO, potentially reducing short- and long-term complication rates. The company is led by CEO and co-founder Jon H. Hoem. Headquartered in Baar, Switzerland, CorFlow has raised more than CHF5M in seed funding to date. It completed a CHF 2.6M first close of a Seed+ round to advance clinical development. The company plans to use the funds to finance the 80-patient First-in-Man MOCA (MVO with CoFI™ System Assessment) clinical trial in Europe and intends the Seed+ as the basis for a larger Series A to secure long-term R&D, clinical, and regulatory activities.

Participated · Series B · Aug 2024

CroíValve is developing the DUO System, a novel transcatheter heart valve that preserves native anatomy and works in tandem with the tricuspid valve to restore function while avoiding contact with critical right-heart structures. The DUO Adapt System features an adaptive coaptation valve designed to fill larger and complex leaks and has shown early clinical use treating leaks up to 35mm with significant reduction in tricuspid regurgitation. The device is investigational and not for sale in any geography. CroíValve plans to expand its TANDEM II prospective, multicenter study across additional US and EU sites to further evaluate safety and performance, building on 15 patients already treated. The company recently expanded its Series B financing and secured grant funding to support this clinical expansion, and has R&D and operations in Ireland with clinical and regulatory functions in the US.